Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Breast 2Other solid neoplasm 1Other 1Gastrointestinal 1

Conditions

Smoldering Multiple Myeloma 2Multiple Myeloma 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leflunomide × Plasma cell × 1 year × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04370483 2026-01-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase EARLY_PHASE1 Active not recruiting
1 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡